Johan Sebregts
Direttore/Membro del Consiglio presso River Biomedics B V I.O.
Posizioni attive di Johan Sebregts
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Segestio BV
 Segestio BV Investment ManagersFinance Segestio BV is an independent private equity firm with its headquarters in Vlissingen, the Netherlands. It was founded in 2012. | Investitore di Private Equity | 01/10/2012 | - |
River Biomedics B V I.O.
 River Biomedics B V I.O. Medical SpecialtiesHealth Technology River Biomedics B V I.O. is a Dutch biotech company that focuses on cardiac drug discovery. The company is based in Enschede, Netherlands. The company develops novel therapies for cardiac diseases by directly targeting the heart muscle using human predictive 3D in-vitro models and human induced pluripotent stem cell (hiPSC) technology. The company aims to address high unmet medical needs and provide detailed clinically relevant read-outs through high-throughput in-house screening platforms. River Biomedics values partnerships and strives for novelty by mimicking nature and connecting biology and engineering. The company was founded by Marcelo Ribeiro, Robert Passier, Lisanne Blauw, and the CEO is Nicky Cooper. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Johan Sebregts
Statistiche
Distribuzione geografica
| Paesi Bassi | 3 |
Posizioni
| Private Equity Investor | 1 |
| Director/Board Member | 1 |
Settori
| Finance | 2 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 2 |
|---|---|
Segestio BV
Segestio BV Investment ManagersFinance Segestio BV is an independent private equity firm with its headquarters in Vlissingen, the Netherlands. It was founded in 2012. | Finance |
River Biomedics B V I.O.
River Biomedics B V I.O. Medical SpecialtiesHealth Technology River Biomedics B V I.O. is a Dutch biotech company that focuses on cardiac drug discovery. The company is based in Enschede, Netherlands. The company develops novel therapies for cardiac diseases by directly targeting the heart muscle using human predictive 3D in-vitro models and human induced pluripotent stem cell (hiPSC) technology. The company aims to address high unmet medical needs and provide detailed clinically relevant read-outs through high-throughput in-house screening platforms. River Biomedics values partnerships and strives for novelty by mimicking nature and connecting biology and engineering. The company was founded by Marcelo Ribeiro, Robert Passier, Lisanne Blauw, and the CEO is Nicky Cooper. | Health Technology |
- Borsa valori
- Insiders
- Johan Sebregts
- Esperienza
